RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032
Overview
The RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market is expected to reach a 9.94 USD Million by 2032 and is projected to grow at a CAGR of 9.15% from 2025 to 2032.
RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market 2018-2032 USD Million
RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 4.95 USD Million
- Projected Market Size (2032): 9.94 USD Million
- CAGR (2025-2032): 9.15%
Key Findings of RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market
- The RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market was valued at 4.95 USD Million in 2024.
- The RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market is likely to grow at a CAGR of 9.15% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Beta Emitters in Isotope Segment accounted for the largest share of the market with a revenue of 4.36 USD Million
- The fastest growing segment Small Molecule Ligands in Vector Type Segment grew Fastest with a CAGR of 9.64% during the forecast period from 2024 to 2032.
RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market Scope
- Research Institutes
- Radiopharmacies
- Hospitals
- Others
- Generator-Produced Isotopes
- Reactor-Produced Isotopes
- Others
- Oncology
- Others
- Monoclonal Antibodies
- Peptides
- Small Molecule Ligands
- Alpha Emitters
- Beta Emitters
RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2024 |
| Unit | Revenue in USD Million |
| Market Value in 2024 | 4.95 USD Million |
| Market Value in 2032 | 9.94 USD Million |
| CAGR (2025-2032) | 9.15% |
| Historic Data | 2016-2023 |
| Market Segments Covered | End User,Sources,Therapeutic Application,Vector Type,Isotope |
Regional Insights:
-
Leading Market (2024-2032): RoSA, leading in terms of revenue 4.95 USD Million in 2024
- Key Country: RoSA, leading in terms of revenue with value of 4.95 USD Million in 2024.
Segments and Scope
-
RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032, By End User
- Hospitals is the largest segment in RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a revenue of 2.96 USD Million in the year 2024.
- Hospitals is the Fastest growing segment in RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a Growth rate of 9.26 % in forecast period 2025-2032.
-
RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032, By Sources
- Reactor-Produced Isotopes is the largest segment in RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a revenue of 3.20 USD Million in the year 2024.
- Reactor-Produced Isotopes is the Fastest growing segment in RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a Growth rate of 9.26 % in forecast period 2025-2032.
-
RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032, By Therapeutic Application
- Oncology is the largest segment in RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a revenue of 3.89 USD Million in the year 2024.
- Oncology is the Fastest growing segment in RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a Growth rate of 9.44 % in forecast period 2025-2032.
-
RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032, By Vector Type
- Small Molecule Ligands is the largest segment in RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a revenue of 2.72 USD Million in the year 2024.
- Small Molecule Ligands is the Fastest growing segment in RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a Growth rate of 9.64 % in forecast period 2025-2032.
-
RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032, By Isotope
- Beta Emitters is the largest segment in RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a revenue of 4.36 USD Million in the year 2024.
- Beta Emitters is the Fastest growing segment in RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a Growth rate of 9.18 % in forecast period 2025-2032.
RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market Company Share Analysis
| Company Name |
|
||
| Novartis AG | |||
| Eckert & Ziegler | |||
| ITM Isotope Technologies Munich SE | |||
| SHINE Technologies, LLC | |||
RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market Geographical Sales Distribution, 2018-2032 USD Million
RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market Company Profiling
Industry Related Reports
Frequently Asked Questions
RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market Scope
- Research Institutes
- Radiopharmacies
- Hospitals
- Others
- Generator-Produced Isotopes
- Reactor-Produced Isotopes
- Others
- Oncology
- Others
- Monoclonal Antibodies
- Peptides
- Small Molecule Ligands
- Alpha Emitters
- Beta Emitters
Frequently Asked Questions
RoSA Alpha and Beta Emitters Based Radiopharmaceuticals Market Company Profiling
Frequently Asked Questions
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.